Article
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Thoracic cancer - 1 May 2022
Tanaka Hisashi, Sakamoto Hiroaki, Akita Takahiro, Ohyanagi Fumiyoshi, Kawashima Yosuke, Tambo Yuichi, Tanimoto Azusa, Horiike Atsushi, Miyauchi Eisaku, Tsuchiya-Kawano Yuko, Yanagitani Noriko, Nishio Makoto
Abstract excerpt
BACKGROUND: Dacomitinib is the second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC). EGFR-TKIs are often re-administered in Japan after the disease progression prior EGFR-TKI. There is little evidence of dacomitinib in rechallenge setting. This study evaluated clinical outcomes of dacomitinib in rechallenge setting. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.